VBI Vaccines is developing novel technologies to expand vaccine protection in large, underserved markets. VBIV’s pipeline includes a cytomegalovirus (CMV) vaccine candidate entering Phase I clinical trials (H116) and a potentially breakthrough immune-oncology glioblastoma (GBM) vaccine candidate currently generating promising preclinical data. VBIV expects to close its reverse merger with SciVac Therapeutics and complete a financing in Q116.
24 Feb 2016
Changing the game in vaccines
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Changing the game in vaccines
VBI Vaccines is developing novel technologies to expand vaccine protection in large, underserved markets. VBIV’s pipeline includes a cytomegalovirus (CMV) vaccine candidate entering Phase I clinical trials (H116) and a potentially breakthrough immune-oncology glioblastoma (GBM) vaccine candidate currently generating promising preclinical data. VBIV expects to close its reverse merger with SciVac Therapeutics and complete a financing in Q116.